Patient-specific tumor-associated antigen-Keyhole limpet hemocyanin-MHC-T cell receptor complex (TAA-KLH-MHC-TCR)

This target represents a complex immunological interaction involving patient-specific tumor-associated antigens (TAAs) and Keyhole Limpet Hemocyanin (KLH) presented by dendritic cells (DCs) to T cell receptors (TCRs) via the Major Histocompatibility Complex (MHC). In this therapeutic model, DCs are harvested from a patient and loaded with TAAs—often unique neoantigens or overexpressed proteins—alongside KLH, which serves as a highly immunogenic carrier protein and adjuvant to enhance the immune response (Harris & Markl, 1999, 'Keyhole limpet hemocyanin (KLH): a biomedical review'). Once re-introduced into the patient, these mature DCs present the processed antigenic peptides on their surface MHC molecules to naive or memory T cells (Banchereau & Palucka, 2005, 'Dendritic cells as therapeutic vaccines against cancer'). The TCRs on endogenous T cells recognize these specific MHC-peptide complexes, initiating a robust, targeted cytotoxic T lymphocyte (CTL) response against the tumor cells (Janeway et al., 2001, 'Immunobiology'). This approach aims to overcome the immune system's tolerance to tumor cells by providing the necessary co-stimulatory signals and high-affinity antigen presentation required for effective anti-cancer immunity. It is primarily utilized in the development of personalized cancer vaccines for various solid and hematological malignancies.

Other names

Personalized dendritic cell vaccineNeoantigen-pulsed dendritic cellsTAA-KLH-DC complexAutologous dendritic cell immunotherapyTumor-associated antigen-KLH conjugate

Ex vivo loading of autologous dendritic cells with patient-specific tumor antigens and KLH adjuvant, followed by re-infusion to trigger MHC-mediated T cell receptor activation and anti-tumor T cell expansion.